GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xeris Biopharma Holdings Inc (LTS:0A8E) » Definitions » Short Interest

Xeris Biopharma Holdings (LTS:0A8E) Short Interest


View and export this data going back to 2021. Start your Free Trial

What is Xeris Biopharma Holdings Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Xeris Biopharma Holdings's Short Interest

For the Biotechnology subindustry, Xeris Biopharma Holdings's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Xeris Biopharma Holdings's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xeris Biopharma Holdings's Short Interest distribution charts can be found below:

* The bar in red indicates where Xeris Biopharma Holdings's Short Interest falls into.


;
;

Xeris Biopharma Holdings Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xeris Biopharma Holdings Inc (LTS:0A8E) » Definitions » Short Interest
Comparable Companies
ZYME PHVS RCUS GYRE NTLA DAWN RCKT REPL VIR MLYS VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
XERS:USA 2B30:Germany
Address
1375 West Fulton Street, Suite 1300, Chicago, IL, USA, 60607
Website
https://www.xerispharma.com
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).

Xeris Biopharma Holdings Headlines

No Headlines